- Cash Position: Cash and cash equivalents were $101.6 million as of March 31, 2025, compared to $34.6 million as of December 31, 2024, bolstered by $76.4 million in gross proceeds from the first ...

Vir Biotechnology’s sidelined hepatitis B candidate, designed to serve as a “functional cure,” has failed to achieve the ...

Vir Bio (VIR) reveals 24-week post-end-of-treatment data from a mid-stage trial for its Hep B therapy developed with Xencor ...

Vir Biotechnology, Inc. progresses HDV treatment with promising ECLIPSE program results. Click here to find out why VIR stock ...

Experts highlight ten common requests received in their Gastroenterology advice and guidance service and explain how these ...

Discover a recent study presented at EASL 2025 that explored the impact of opt-out testing for blood-borne viruses in ...

Medically reviewed by Stella Bard, MD A rheumatoid factor (RF) test detects rheumatoid factor, a type of antibody (proteins ...

A pioneering study uncovers crucial immune dynamics in hepatitis B, offering new insights into how immune responses evolve ...

These scientists sought to answer a simple question. They ended up stumbling upon a discovery that could pave the way for a ...

Fewer than 1 in 3 children with hepatitis C (HCV) see a clinician for care, and fewer than 1 in 8 receive treatment.

Dutch biotech Avidicure has launched with $50 million in seed financing to support development of a novel class of multifunctional antibody therapies for cancer. The funding round, announced Thursday, ...

2020; Wragg et al., 2022)]. Host antibody responses due to recent infection or previous exposure are heritable, and the genetic factors influencing these traits have been explored for several human ...